MedTrace Logo

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

NCT03354429 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11016

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Conditions

  • Acute Ischaemic Stroke
  • Transient Ischaemic Attack

Interventions

DRUG

Ticagrelor

Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.

DRUG

Placebo

Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2019-12-13
Completion
2019-12-13

Countries

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • China
  • Czechia
  • France
  • Germany
  • Hong Kong
  • Hungary
  • India
  • Italy
  • Mexico
  • Peru
  • Poland
  • Romania
  • Russia
  • Saudi Arabia
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • Ukraine
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03354429 on ClinicalTrials.gov